20 August 2013
Scancell Holdings Plc
Inclusion on the Quotation Board of the Open Market of the Frankfurt Stock Exchange
Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that the Company's ordinary shares have been included on the Quotation Board of the Open Market of the Frankfurt Stock Exchange with effect from today. Scancell has appointed ACON Actienbank AG as Listing Coordinator for providing the quote on the Borse Frankfurt (Frankfurt Stock Exchange) under the symbol "SCP".
The compliance listing is in addition to Scancell's existing listing on the AIM market of The London Stock Exchange.
Richard Goodfellow, Joint CEO of Scancell, said:
"Following meetings earlier in the year and our recent successful fundraising, we have received significant interest in the Company from German investors. A quotation on the Borse Frankfurt gives these investors the opportunity to trade in Scancell and alongside our London listing. We anticipate that having this Frankfurt listing will encourage regular trading by German retail investors, enhance liquidity in the Company's shares and create a broad investor base to allow greater visibility amongst the European investment community. The coming year is pivotal for Scancell as we await results from clinical trials on SCIB1 in malignant melanoma and the further development of our Moditope™ platform."
For Further Information:
Scancell Holdings Plc |
+44 (0) 74 2323 0 497 |
Dr Richard Goodfellow, Joint CEO |
|
Professor Lindy Durrant, Joint CEO |
|
|
|
Cenkos Securities: |
+44 (0) 20 7397 8900 |
Camilla Hume |
|
Stephen Keys |
|
|
|
FTI Consulting |
+44 (0) 20 7831 3113 |
Simon Conway |
|
Mo Noonan |
|
|
|
Dr. Reuter Investor Relations |
+49 251 980 1561 |
Eva Reuter |
|
Kim von Ahn |
|
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
